KeyBank National Association
ACHN

KeyBank National Association’s Achillion Pharmaceuticals ACHN Stock Holding History

KeyBank National Association’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-13,000
Closed -$43K – 1308
2013
Q4 		$43K Buy
+13,000
New +$37.7K ﹤0.01% 1261

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

KeyBank National Association's ACHN Position: Q1 2014 in Review

KeyBank National Association sold out of Achillion Pharmaceuticals (ACHN) in Q1 2014, closing a stake of 13,000 shares — an estimated $43K sold.

KeyBank National Association first reported a position in ACHN in Q4 2013 and held it in 1 quarter. The position peaked at $43K in Q4 2013. 94 funds tracked by Wall St. Rank hold ACHN as of Q1 2014.

  • KeyBank National Association reported no remaining Achillion Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • KeyBank National Association sold 13,000 Achillion Pharmaceuticals shares in Q1 2014, an estimated $43K.
  • KeyBank National Association first reported a position in Achillion Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • KeyBank National Association's Achillion Pharmaceuticals position peaked at $43K in Q4 2013.
  • 94 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2014.

Based on KeyBank National Association's 13F filing for Q1 2014, filed 14 May 2014.